Welcome to our dedicated page for IDEXX Laboratories SEC filings (Ticker: IDXX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The IDEXX Laboratories, Inc. (IDXX) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a NASDAQ-listed, S&P 500 company focused on pet healthcare innovation, veterinary diagnostics, and software, IDEXX uses SEC filings to report financial results, material agreements, and governance changes that matter to shareholders and analysts.
Among the most closely watched documents are annual reports on Form 10‑K and quarterly reports on Form 10‑Q, which describe IDEXX’s business, risk factors, and detailed financial statements, including performance in areas such as the Companion Animal Group, Water, and Livestock, Poultry and Dairy. Current reports on Form 8‑K provide timely updates on specific events, such as quarterly earnings releases, amendments to credit agreements, and board or leadership changes. For example, IDEXX has filed 8‑Ks describing an amendment to a credit agreement that provides unsecured revolving and term loan facilities for general corporate purposes, as well as filings that furnish earnings press releases.
Investors can also use this page to monitor proxy statements for information on board structure and executive compensation, and Form 4 insider transaction reports when available, which show purchases and sales of IDXX shares by directors and officers.
Stock Titan enhances these filings with AI-powered summaries that explain key points in plain language, helping users navigate lengthy documents such as 10‑Ks and 10‑Qs. Real-time updates from EDGAR mean new IDEXX filings appear promptly, while AI highlights important items like changes in leverage arrangements, governance updates, and trends in reported results. This makes it easier to understand how IDEXX’s regulatory disclosures relate to its veterinary diagnostics, software, and animal health businesses.
Andrew Emerson, EVP, CFO and Treasurer of IDEXX Laboratories (IDXX), reported insider transactions dated 08/07/2025. The filing shows an acquisition of 1,849 common shares at $141.60 and a disposition of 402 common shares at $650.06. Following the reported transactions, beneficial ownership is shown as 4,272.778 shares (direct) after the acquisition and 3,870.778 shares (direct) after the disposition. The filing notes 27.3420 shares purchased under the employee stock purchase plan on March 31, 2025 and June 30, 2025, and references a grant of an option to buy 1,849 shares that vested on February 14, 2022. The form is signed by an attorney-in-fact on 08/11/2025.
Idexx Laboratories insider transaction disclosed via Form 144. The filing reports a proposed sale of 1,200 common shares through Morgan Stanley Smith Barney with an aggregate market value of $787,840.20. The shares were acquired by exercise on 08/06/2025 and payment was made in cash. With 80,004,694 shares outstanding, the proposed sale represents approximately 0.0015% of the company’s outstanding common stock.
The filing also lists three sales by NIMRATA K HUNT on 08/06/2025 totaling 7,143 shares and gross proceeds of $4,503,160.86. The filer affirms they are not aware of any material nonpublic adverse information about the issuer.
Idexx Laboratories executive Nimrata Hunt reported option exercises and market sales on 08/06/2025. The filing shows conversion of non-qualified stock options into common stock for 1,218, 5,865 and 5,711 shares at strikes of $141.60, $178.26 and $206.94 respectively, and three open-market sales totaling 7,143 shares at prices between $630.6891 and $630.9087. The reporting person owned 25,149.9435 shares before the sales and owned 18,006.9435 shares directly after the transactions, with an additional 160 shares held indirectly (jointly with spouse). The Form documents the mechanics of option-to-share conversion and subsequent sales without stating motives.
Jonathan Jay Mazelsky, President and CEO and a director of IDEXX Laboratories (IDXX), reported a series of transactions dated 08/06/2025. He acquired 29,260 shares by exercising non-qualified stock options at an exercise price of $67.85 per share and sold a matching total of 29,260 common shares the same day in multiple tranches at reported weighted-average prices between $626.9024 and $639.3718 per share. The reported sales reduced his direct holdings from 112,571.3016 shares to 83,311.3016 shares. Based on the reported quantities and prices, the aggregate gross proceeds from the sales are approximately $18.49 million. The filing also references an option grant to buy 41,260 shares that became exercisable in five annual installments beginning 02/14/2017.
Michael Lane, Executive Vice President of Idexx Laboratories (IDXX), reported multiple stock and option transactions dated 08/06/2025. The filing shows acquisitions of 1,286 and 7,125 shares (prices listed as $206.94 and $288.78), and dispositions of 5,631, 2,480 and 300 shares at weighted-average prices of $627.5634, $627.9911 and $628.8866, respectively. After these transactions the filing reports total direct beneficial ownership of 7,131.9435 shares and an additional 592 shares held indirectly by the reporting person’s spouse in an IRA.
The filing also lists non-qualified stock option awards related to the reporting person: a right associated with 1,286 underlying shares (exercise price $206.94) and a right associated with 7,125 underlying shares (exercise price $288.78). Explanations note prior grants exercisable in installments beginning in 2020 and 2021 and purchases of 28.7090 shares under the issuer’s Employee Stock Purchase Plan.
IDEXX Laboratories Inc. filed a Form 144 to register the proposed sale of 5,450 shares of common stock, with an aggregate market value of $3,551,220.00, to be sold on NASDAQ through Morgan Stanley Smith Barney LLC. The filing lists 80,004,694 shares outstanding and shows an approximate sale date of 08/08/2025.
The shares were acquired via a stock option exercise on 08/08/2025 and paid in cash. The filer reports "Nothing to Report" for securities sold during the past three months and includes the standard attestation about material nonpublic information and trading-plan language. The provided content does not show a populated notice date or signature block.
Form 144 summary for IDEXX Laboratories, Inc. (IDXX)
This Form 144 reports a proposed sale of 7,143 shares of Common stock through Morgan Stanley Smith Barney LLC on NASDAQ with an aggregate market value of $4,503,160.87. Shares outstanding are listed as 80,004,694. The approximate date of sale is 08/06/2025.
The securities were acquired by stock option exercise on 08/06/2025 from the issuer and payment is listed as cash. The filing states "Nothing to Report" for securities sold during the past three months. Several filer and issuer contact fields (CIK, submission contact name/phone/email, date of notice, signature) are not provided in the extract.